Genocea Biosciences (GNCA) Misses Q3 EPS by 2c

Genocea Biosciences (NASDAQ: GNCA) reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).

Third Quarter 2020 Financial Results

• Cash position: As of September 30, 2020, cash and cash equivalents were $87.6 million versus $40.1 million as of December 31, 2019.
• Research and Development (R&D) expenses: R&D expenses were $7.5 million for the quarter ended September 30, 2020, compared to $6.8 million for the same period in 2019.
• General and Administrative (G&A) expenses: G&A expenses were $3.6 million for the quarter ended September 30, 2020, compared to $2.8 million for the same period in 2019.
• Net loss: Net loss was $4.6 million for the quarter ended September 30, 2020, compared to $7.5 million for the same period in 2019.

Guidance
Genocea expects that its existing cash and cash equivalents are sufficient to support its operations to mid-2022.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year